key: cord-1020847-rfam3no2
authors: Venzon, Mericien; Bernard-Raichon, Lucie; Klein, Jon; Axelrad, Jordan E.; Hussey, Grant A.; Sullivan, Alexis P.; Casanovas-Massana, Arnau; Noval, Maria G.; Valero-Jimenez, Ana M.; Gago, Juan; Wilder, Evan; Thorpe, Lorna E.; Littman, Dan R.; Dittmann, Meike; Stapleford, Kenneth A.; Shopsin, Bo; Torres, Victor J.; Ko, Albert I.; Iwasaki, Akiko; Cadwell, Ken; Schluter, Jonas
title: Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocation
date: 2021-07-27
journal: Res Sq
DOI: 10.21203/rs.3.rs-726620/v1
sha: c22ca1e230127ecff51d62c92358f43b94404a78
doc_id: 1020847
cord_uid: rfam3no2

The microbial populations in the gut microbiome have recently been associated with COVID-19 disease severity. However, a causal impact of the gut microbiome on COVID-19 patient health has not been established. Here we provide evidence that gut microbiome dysbiosis is associated with translocation of bacteria into the blood during COVID-19, causing life-threatening secondary infections. Antibiotics and other treatments during COVID-19 can potentially confound microbiome associations. We therefore first demonstrate that the gut microbiome is directly affected by SARS-CoV-2 infection in a dose-dependent manner in a mouse model, causally linking viral infection and gut microbiome dysbiosis. Comparison with stool samples collected from 101 COVID-19 patients at two different clinical sites also revealed substantial gut microbiome dysbiosis, paralleling our observations in the animal model. Specifically, we observed blooms of opportunistic pathogenic bacterial genera known to include antimicrobial-resistant species in hospitalized COVID-19 patients. Analysis of blood culture results testing for secondary microbial bloodstream infections with paired microbiome data obtained from these patients suggest that bacteria translocate from the gut into the systemic circulation of COVID-19 patients. These results are consistent with a direct role for gut microbiome dysbiosis in enabling dangerous secondary infections during COVID-19.

In agreement with a recent study associating gut microbial compositions with disease severity 4 , 123 we found that samples from patients who were treated in the ICU had reduced bacterial diversity 124 (Supplementary Figure S3) . In 22 cases, gastrointestinal symptoms were recorded, but only two of 125 those patients required ICU treatment and corresponding stool samples had higher average diversity than 126 other samples (Supplementary Figure S3) . Strikingly, however, samples associated with a BSI had 127 strongly reduced bacterial α-diversities (mean difference: -7.7, CIBEST[-10.2, -5.2], Supplementary Figure  128 S3). 129

The lower diversity associated with samples from 21 patients with BSIs led us to investigate their 130 bacterial taxon compositions and the potential that gut dysbiosis was associated with BSI events. All BSI 131 patients had received antibiotic treatments during hospitalization, which could exacerbate COVID-19 132 induced shifts in microbiota populations 11,12,15 , but may indeed be administered in response to a 133 suspected or confirmed BSI. However, we noted that most BSI patients (80%) also received antibiotics 134 prior to their BSI. Principal coordinate analysis of all stool samples indicated that the BSI-associated 135 samples spanned a broad range of compositions (Figure 3a) . To identify bacterial abundance patterns 136 that consistently distinguished BSI from non-BSI-associated samples, we next performed a Bayesian 137 logistic regression. This analysis estimated the association of the 10 most abundant bacterial genera with 138 BSI cases, i.e. it identified enrichment or depletion of bacterial genera in BSI associated samples 139 (Figure 3b ). This analysis revealed that the genus Faecalibacterium was negatively associated with BSI 140 (OR: -1.49, CI:[-2.82, -0.18]). Faecalibacterium is an immunosupportive Clostridiales genus that is a 141 prominent member of the human gut microbiome 30-32 , and its reduction is associated with disruption to 142 intestinal barrier function 33,34 , perhaps via ecological network effects 34 . 143

To evaluate the effect size of the association between Faecalibacterium and BSIs, we performed 144 a posterior predictive check. Using the average genus composition found across all samples, we first 145 computed the distribution of predicted BSI risks (Figure 3c) , and compared this risk distribution with a 146 hypothetical bacterial composition which increased Faecalibacterium by 10% points. The predicted risk 147 distributions associated with these two compositions differed strongly (mean difference 26%, 148 CI: [-9%, 67%], Figure 3c ). Domination states of the microbiome increase the risk for BSIs in 149 immunocompromised cancer patients 13 ; such dominations imply high relative abundances of single taxa, 150 and therefore a low diversity. Consistent with this, Faecalibacterium abundance was positively correlated 151 with diversity (R: 0.55, p<10 −10 , Figure 3d ) in our data set and as reported previously 30 . 152

We therefore next investigated a direct association between the bacteria populating the gut 153 microbiome and the organisms identified in the blood of patients. Visualizing the bacterial composition in 154 stool samples from patients alongside the BSI microorganism (Supplementary Figure S4, Figure 3e ) 155 suggested a correspondence with the respective taxa identified in the blood: high abundances of the BSI-156 causing microbes were found in corresponding stool samples (Figure 3e) . To analyze this, we first 157 assigned stool samples associated with each BSI event into 5 categories defined by the taxonomic order 158 of the causative bacterial organisms, as well as one singleton group of a fungal infection case as a sixth category; stool samples from uninfected patients were assigned a seventh, "uninfected" category. For 160 samples of each BSI category, we first calculated their median abundances of bacterial predictors in the 161 stool. We then ranked these stool taxon median abundances across BSI categories. As expected from 162 the visualization of sample compositions (Figure 3e) , we found that BSI category sample sets were 163 generally enriched in their respective taxa in the stool. For example, samples associated with Klebsiella, 164

Escherichia or Serratia BSIs (Enbct category, Figure 3f ) had the highest rank of Enterobacterales 165 abundances across the BSI category sample sets (Figure 3f) . We tested this observation statistically 166 using the log10-relative bacterial abundances in stool samples as independent predictors of identified BSI 167 pathogens, i.e. the BSI category, in a Bayesian categorical regression model where the uninfected class 168 was used as a pivot (see methods). In addition to taxon abundances, the model included the bacterial 169

α-diversity as a predictor. As expected, a strong statistical association between diversity and BSIs in One limitation of our data is temporal ordering of samples. Occasionally stool samples were 204 collected after observation of BSI, and this mismatch in temporal ordering is counter intuitive for gut-to-205 blood translocation and a causal interpretation of our associations. However, the reverse direction, that 206 blood infection populates and changes the gut community, is unlikely for the organisms identified in the 207 blood, and if our associations were not causal, we would expect no match between BSI organisms and 208 stool compositions. 209

Taken together, our findings support a scenario in which gut-to-blood translocation of 210 microorganisms following microbiome dysbiosis, a known issue for chronic conditions such as cancer, 211 leads to dangerous BSIs during COVID-19. We suggest that investigating the underlying mechanism 212 behind our observations will inform the judicious application of antibiotics and immunosuppressives in 213 patients with respiratory viral infections and increase our resilience to pandemics. Tisch Hospital, New York City, between January 29, 2020 -July 2, 2020 and were followed until 261 discharge. In order to be eligible for inclusion in the study, stool specimens needed to be from individuals 262 >18 years of age. Data including demographic information, clinical outcomes, and laboratory results were 263 extracted from the electronic medical records in the NYU Langone Health clinical management system. 264

Blood and stool samples were collected by hospital staff. OmnigeneGut kits were used on collected stool. Within the workflow, the paired FASTQ reads were trimmed, and then filtered to remove reads containing 295 Ns, or with maximum expected errors >= 2. The dada2 learn error rate model was used to estimate the 296 error profile prior to using the core dada2 algorithm for inferring the sample composition. Forward and 297 reverse reads were merged by overlapping sequence, and chimeras were removed before taxonomic 298 assignment. ASV taxonomy was assigned up to genus level using the SILVAv.138 database with the 299 method described in 45 Bray-Curtis distances were calculated from the filtered ASV table using QIIME 1.9.1 and principal 308 components of the resulting distance matrix were calculated using the scikit-learn package for the Python 309 programming language, used to embed sample compositions in the first two principal coordinates (see To interrogate a correspondence between the taxon abundances in stool samples and the 358 microorganisms causing BSIs, we performed a Bayesian categorical regression. Briefly, we chose to 359 investigate an association between stool taxon abundances (independent predictor variable) and the 360 microbe identified in the blood (categorical outcome variable with seven unordered values) using a 361 multiclass regression (categorical regression). We estimated for each sample a probability of being 362 associated with one of the 6 BSI types (i.e. BSI by: Bacteroidaceae, Enterobacteriaceae, 363

Lactobacillaceae, Pseudomonadaceae, Staphylococcaceae, Saccharomycetaceae), and we used a 364 seventh class, uninfected, as a pivot. This means we are estimating a seven component simplical vector 365 (s) containing the probabilities of a sample to be associated with one of the seven categories (6 BSI types 366 and uninfected). For each category, we set up a linear model (sg, where g indicates the category). Each 367 linear model includes log10-relative stool taxon abundances of the taxa corresponding to the BSI category. 368

Furthermore, we had shown that alpha diversity (IVS) was globally associated with BSI; thus, diversity 369 was a predictor in each linear model. We set up a model using varying intercept and varying slope terms 370 such that the linear models used partially pooled coefficients for baseline risks (β [1] 

Where p corresponds to the probabilities of each category, β is a two-component variable for the intercept 394 and slope terms, representing the global baseline probability of bacterial infections with Bacteroidaceae, 395

Enterobacteriaceae, Lactobacillaceae, and Pseudomonadaceae as well as the global slope coefficient for 396 the effect of stool log10-relative abundances, which are partially pooling information across bacterial 397 infection categories. To achieve partial pooling and account for correlations between varying intercepts 398 and slopes (z), we jointly inferred the Choleski-factorized covariance matrix (σp, Lp, zp), using the 399 Lewandowski-Kurowicka-Joe (LKJ) distribution as a prior (LKJ_corr_choleski). βdiversity is the coefficient for 400 the effect of the IVS diversity. Of note, 16S rRNA sequencing does not provide abundances for the fungal 401 infection by Saccharomycetaceae; therefore, we used only a baseline risk for this infection type 402

(αSaccharomycetaceae) and IVS as predictors. To ensure equal prior probabilities for this category relative to the 403 other categories, which have an additional predictor term and thus wider prior probabilities, we 404 compensated the otherwise reduced prior uncertainty by widening the prior for αSaccharomycetaceae. Also, we 405 assumed that infections by Staphylococcaceae could sometimes include contaminations from the skin of 406 the patient or staff; therefore, we did not pool estimates for BSIs by Staphylococcaceae with other 407 coefficients. The model was implemented in the STAN programming language and compiled using 408 cmdstan. Code, the compiled STAN model, R notebooks to obtain and process the posterior chains, and 409 data tables are provided in the supplement (Supplementary File 2) . 410

All data is made available as Supplementary. We provide code and data to reproduce the main analyses 413

in the form of jupyter notebooks and R notebooks, alongside processed "tidy" data tables, compiled STAN 414 programs and code to regenerate the figures. The raw sequencing data have been deposited on the 415 Sequencing Reads Archive (SRA), and SRA accession numbers are available for two bioprojects 416 corresponding to the mouse sequencing data (Supplementary File 3) Table S1 ). 427 

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Gut microbiota composition reflects disease severity and dysfunctional immune 511 responses in patients with COVID-19

Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New 513

York City pandemic surge

Hospital-Acquired Infections in Critically Ill Patients With COVID-19

Bacterial co-infection and secondary infection in patients with COVID-19: a 517 living rapid review and meta-analysis

Precision microbiome reconstitution restores bile acid mediated resistance to 519 Clostridium difficile

Microbiota-mediated colonization resistance against intestinal 521 pathogens

Antibiotics and the gut microbiota

Antibiotic-Induced Shifts in Fecal Microbiota Density and Composition during 525

Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-527 lactamase resistance

Intestinal domination and the risk of bacteremia in patients undergoing allogeneic 529 hematopoietic stem cell transplantation

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal 531 microbiota transplant

Compilation of longitudinal microbiota data and hospitalome from hematopoietic cell 533 transplantation patients

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic

Low prevalence of bloodstream infection and high blood culture contamination rates in 537 patients with COVID-19

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-539 Infected Pneumonia in Wuhan, China

Bacterial coinfections in coronavirus disease 2019

Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York 543

Co-infections in people with COVID-19: a 545 systematic review and meta-analysis

Recommendations for antibacterial therapy in adults with COVID-19 -an 547 evidence based guideline

High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding 549 invasive candidiasis

Impact of gut colonization with butyrate-producing microbiota on respiratory viral 551 infection following allo-HCT

The microbial metabolite desaminotyrosine protects from influenza through type I 553 interferon

Commensal bacteria calibrate the activation threshold of innate antiviral immunity

Microbiota regulates immune defense against respiratory tract influenza A virus 557 infection

Influenza infection impairs the gut's barrier properties and favors secondary enteric 559 bacterial infection through reduced production of short-chain fatty acids

Respiratory influenza virus infection induces intestinal immune injury via microbiota-562 mediated Th17 cell-dependent inflammation

The gut microbiota is associated with immune cell dynamics in humans

Gut microbiome modulates response to anti-PD-1 immunotherapy in 566 melanoma patients

Microbial dysbiosis is associated with aggressive histology and adverse 568 clinical outcome in B-cell non-Hodgkin lymphoma

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified 570 by gut microbiota analysis of Crohn disease patients

Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the 573 production of mucus glycans and the development of goblet cells in the colonic epithelium of a 574 gnotobiotic model rodent

Evolution of antibody immunity to SARS-CoV-2

Detection of SARS-CoV-2 in Fecal Samples From Patients With Asymptomatic and 577 Mild COVID-19 in Korea

Evidence for Gastrointestinal Infection of SARS-CoV-2

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in 581

Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis

SARS-CoV-2 productively infects human gut enterocytes

An observational cohort study of bacterial co-infection and implications for empirical 586 antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London

Autophagy protein ATG16L1 prevents necroptosis in the intestinal 589 epithelium

Type I IFNs and CD8 T cells increase intestinal barrier permeability after 591 chronic viral infection

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, 593 and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

Systematic improvement of amplicon marker gene methods for increased accuracy 596 in microbiome studies

Naive Bayesian classifier for rapid assignment of 598 rRNA sequences into the new bacterial taxonomy

Modelling and analysis of 600 compositional data

Bayesian estimation supersedes the t test

The No-U-Turn Sampler: Adaptively Setting Path Lengths in 604

We thank René Niehus for helpful discussions on the implementation of the various Bayesian analyses. 458 We thank the NYU Langone's Genome Technology Center supported in part by NYU Langone Health's 459